The in vitro Effect of Doxorubicine-G2-FA Treatment on Breast Cancer Copyright

Abstract

BACKGROUND: To achieve delivery of a drug to tumors, folic acid (FA) was used as a targeting ligand to change nanocarriers. Since the folate receptor has more expression in several tumor types such as breast cancer. OBJECTIVES: The present study aimed to evaluate the effect of Doxorubicine-G2-FA (Dox- G2-FA) with in vitro assays. The abbreviation of G2 represents the second generation of dendrimer synthesis. METHODS: For this purpose, Dox-G2-FA was synthesized and mass spectroscopy was used to confirm the synthesized component. Also, MTT assay, flow cytometry, and gene expression assay by real-time PCR were used to evaluate cell viability, apoptosis, and necrosis. RESULTS: In this study, the effect of Dox and Dox-G2-FA on the expression of Bax, Bcl2 genes showed that there was a significant decrease in the expression of the Bcl2 gene in the Dox-G2-FA group compared to Dox and control groups( P<0.05). Also, the results of flow-cytometry showed that apoptosis in the presence of Dox-G2-FA was greater than in the Dox group ( P<0.05). CONCLUSIONS: Therefore, it seems that the effect of Dox-G2-FA on apoptosis is better than the effect of Dox usage alone.

Keywords

• apoptosis
• bax
• bcl2
• breast cancer
• doxorubicine-g2-folate